Pharmaceuticals - Community Register


List of refusals for human medicinal products


Product name: Nerventra
Active substance: laquinimod
Indication: Nerventra is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS)
Marketing Authorisation Holder: Teva Pharma GmbH

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
21/08/2014 Centralised - Refusal of marketing authorisation EMEA/H/C/2546 (2014)6039 of 19/08/2014